Our Take
Sangamo invented the field but lost to CRISPR's simplicity and cost; the bankruptcy auction is a controlled dismantling, not a failure of the science.
Why it matters
This marks the end of an era for ZFN-based therapies and shows how a platform pioneer can be displaced by a simpler alternative even with validated clinical data. The asset fragmentation to competing pharma firms signals that Sangamo's technology still has value—just not at scale or as a standalone company.
Do this week
Gene therapy teams: audit your manufacturing and IP dependencies on any Sangamo platform; clarify which acquirer (Lilly or Astellas) now controls your partner programs before the auction closes.
Sangamo files Chapter 11; Lilly and Astellas acquire core platforms
Sangamo Therapeutics, the Bay Area biotech founded in 1995 as a pioneer in zinc-finger nuclease (ZFN) gene editing, filed for Chapter 11 bankruptcy protection in Delaware. Concurrent with the filing, the company entered asset sale agreements with Eli Lilly and Astellas Pharma, who have agreed to serve as "stalking horse" bidders in a future bankruptcy court auction.
Eli Lilly will acquire Sangamo's capsid delivery platform, ZFN platform, modular integrase (MINT) platform, and its prion disease program (ST-506). Astellas will take over the Fabry disease program, isaralgagene civaparvovec (ST-920), which showed sustained efficacy in a Phase I/II trial where all 25 dosed patients maintained elevated α-Gal A levels up to three years post-treatment.
Three programs remain available for other bidders: the clinical-stage ST-503 for chronic neuropathic pain, giroctocogene fitelparvovec for hemophilia A, and Sangamo's cell therapy and regulatory T cell (Treg) assets. CEO Sandy Macrae framed the process as value-maximizing, though Sangamo reported a $31 million net loss on $1.4 million in revenue in the most recent quarter—a 78% revenue decline year over year (per company filing).
A 30-year inventor loses to speed and cost
Sangamo was not a failed company; it was a displaced one. Founded by Ed Lanphier after he recognized the potential of engineered zinc-finger proteins for gene editing, the company became the first gene editing platform to reach the clinic and demonstrated the concept of controlled genome editing in human DNA. That foundational work earned the field the term "genome editing" itself.
But CRISPR arrived in 2012–13 and shifted the entire industry. Lanphier later acknowledged in interviews that CRISPR's simplicity and lower manufacturing cost made it dominant in drug development, even though he had regarded it as nonspecific and immunogenic compared to ZFNs. The clinical proof-of-concept for ST-920 in Fabry disease (with FDA alignment on Accelerated Approval pathway in 2024) was not enough to overcome the head start and installed base of CRISPR-focused competitors.
The bankruptcy is orderly, not chaotic. Two major pharmaceutical firms are willing to bid on Sangamo's assets, suggesting the underlying technology and pipeline still have commercial utility—just not as a public-market bet. The fragmentation to Lilly and Astellas, however, means Sangamo's integrated platform strategy is dissolving. What once might have been a single genomic medicine company is now a collection of licensed programs inside larger organizations.
Audit your dependencies now
If your team relies on any Sangamo platform technology, manufacturing partnerships, or regulatory alignment (particularly around ZFN or AAV capsid delivery), the stalking horse process creates a window of uncertainty. Clarify which acquirer controls your program and confirm continuity of supply chain, regulatory pathway, and licensing terms before the final auction closes. Pfizer's termination of a hemophilia A collaboration with Sangamo six months after positive Phase III data shows how quickly partnerships can unwind; do not assume continuity.
For those developing competing platforms or therapies in the same rare disease space, this auction will reveal bid prices and strategic interest in ZFN and MINT technologies. Use that signal to benchmark your own IP valuation and partnership attractiveness.